Pharmacy - Articles

This summit aims to provide both strategic and practical information that will ensure that organisations can prepare for and survive what is now considered to be the inevitable pandemic. Professor Hugh Pennington from the Department of Medical Microbiology at University of Aberdeen will repeat his warning that, “Only one thing is certain and that is that there will be a pandemic.”
The topics to be covered at the Summit will stress that comprehensive plans must cover seemingly diverse aspects such as legal policy, staff travel, quarantine arrangements, as well as controlling rumour, speculation and scaremongering that can easily rage out of control If you or your team wish to attend , you can email me or register through one of the options below. You can view the programme and…

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Rlapse rates high Unfortunately, relapse rates following treatment for AML and ALL are high, and current treatments offer little chance of long-term survival for most patients. While developmental drugs in this area have the opportunity to garner orphan drug designation and fast track approval status by the FDA, given the niche nature of treatments for this form of cancer, the return on investment for developers of novel…

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
WHAT YOU WILL TAKE AWAY FROM THIS CONFERENCE We believe that the quality of a conference program comes from listening to the requests and advice given by our target market. We pride ourselves in providing the most-up-to date subject matter suggested by the market in an environment that is conducive to networking and learning. At this event, you will have the unique opportunity…

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
According to our quick RSS survey, 68% of respondents had no idea what it was or how to use it. This is a shame as we, and many other sites in the pharmaceutical industry are  providing them.So lets start with "what is RSS?" - essentially its a data standard that allows data to be made available in a format that can be easily picked up by a simple reader you install on your computer. In reality there are several standards, but most reader software reads them all. What this means to you is that by installing a small piece of software, you can elect to collect news (or whatever information sites make available) from across the web, and collect them into a si…

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Over the last 8 years, Pharmaceutical companies and groups did not consider any move that attracts and recruit leads in the best cost effective way. Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy. elias KAI www.Google-kai.com

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's at…

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
Heart failure affects more than 5 million people in the , and 550,000 new cases are diagnosed each year. It is the most common cause of hospitalization in people older than 65 years of age. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care…

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.  Pabord is relevant to service providers and R&D organisations active across the entire discovery and development chain from lead generation to product registration

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The dynamics of the pain market have however altered greatly over the past few years, in particular as a result of the troubles surrounding the multi-bi…

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June.  Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.  Why should you attend this event?  Including real industry case studies from Pfizer, Novartis, Orion Pharma, Takeda UK, Chiesi Farmaceutic…

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences. How could I lose? The potential of new technologies such as genomics and monoclonal antibodies appeared to be huge. On top of that, I knew that most people in the developed world were living longer and becoming richer too. Buying shares in drugs companies was close to a sure thing! As time went on, I began…

Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
DailyUpdates March 1st, 2006: Genentech and Biogen Idec announced yesterday (press release) that the FDA has approved Rituxan (Rituximab) in combination with methotrexate to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Approved by the FDA in November 1997, Rituxan was the first therapeutic antibody approved for treating cancer in the . A supplemental Biological License Application (sBLA) was approved for Rituxan in April 2001, a…

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
1. Can you describe ICON for me in a single sentence? ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.2. How and when did ICON start? ICON was founded in 1990 by Dr. John Climax and Dr. Ronan Lambe. Originally launched with just five staff all based in Dublin, we grew organically for our first 10 years, making our first acquisition in 2000. We now have 3000 staff operating from 41 offices across 27 countries. 3. Why do you think ICON is so successful?The quality of our peop…

A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability.
A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability. Abbott had an excellent 2004, according to its CEO, Miles White: it achieved double-digit growth in both of its business groups. How was this managed in the face of what is perhaps the most difficult business environment the healthcare industry has ever faced– and one that is not expected to improve significantly in the foreseeable future? How has Abbott navigated this extremely difficult environment while simultaneously transforming the company into anorganisation better prepared to overcome the same challenges in the futu…

Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the United States – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it?
Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it? In April 2005, Miles White, Abbott’s CEO, summed up the previous year’s performance in one word – “Excellent”. Five years ago, it was clear that the company would have to reposition itself yet again in…

In their study due to be published in the March edition of Bioorg Med Chem Lett, Hoffmann and colleagues from Roche describe the design of two promising NK1 receptor antagonists, netupitant and befetupitant.
DailyUpdates February 23rd, 2006: The tachykinins were first identified in 1931 however realization of the therapeutic potential of antagonists that block their action has only taken place over the last decade. Tachykinin receptor antagonists have been implicated in various conditions such as depression/anxiety, pain, airway disease, incontinence, nausea and bowel disorders. The tachykinins are the products of two genes, preprotachykinin I which produces substance P (SP) and neurokinin (NK)A and preprotachykinin II which produces NKB. In 1986 the research community classified the tachy…

Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to compan…

The approval of Novartis’ Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartis’ second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
A devastating disease with a poor prognosis for many patients, until recently CML has had few treatment options and, for the most part, these have succeeded only in delaying disease progression by up to a few years. Chronic myeloid leukaemia (CML) is a myeloproliferative disorder affecting 1 to 2 people per 100,000 annually. These disorders…

The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitor’s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Obesity is an active area of R&D and numerous novel molecular targets are currently being evaluated. One target, ghrelin was the subject of a major target discovery report from LeadDiscovery published in 2003 Ghrelin: Pharmaceutical & Ther
The prevalence of obesity has increased by 61% in the during the period 1991-2001. According to Datamonitor’s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Even though there is an increasing awarene…

The symptoms of Alzheimer’s disease can be treated by a class of drugs known as cholinesterase inhibitors (ChEI’s), which increase the availability of acetylcholine in the brain by inhibiting the enzyme acetylcholinesterase (AChE).
Dementia is a neurodegenerative and devastating disease Dementia is a degenerative disease of the brain that progressively destroys the neurons controlling memory, language and reasoning. It progresses at different rates in different people. It is estimated that dementia currently affects nearly 18 million people worldwide (1). As the mean age of the population increases, these numbers are steadily increasing. Forms of dementia and their estimated prevalence: 1 Alzheimer's disease (AD) 55% Vascular dementia (VaD)20% Dementia with Lewy bodies (DLB) and dementia…